[1] Spellberg B,Edwards J Jr,Ibrahim A.Novel perspectives on mucormycosis:pathophysiology,presentation,and management[J].Clin Microbiol Rev,2005,18(3):556-569. [2] Chayakulkeeree M,Ghannoum MA,Perfect JR.Zygomycosis:the re-emerging fungal infection[J].Eur J Clin Microbiol Infect Dis,2006,25(4):215-229. [3] Ameen M,Arenas R,Martinez-Luna E,et al.The emergence of mucormycosis as an important opportunistic fungal infection:five cases presenting to a tertiary referral center for mycology[J].Int J Dermatol,2007,46(4):380-384. [4] Liang X,Bi S,Yang W,et al.Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination[J].Vaccine,2009,27(47):6550-6557. [5] De Pauw B,Walsh TJ,Donnelly JP,et al.Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group[J].Clin Infect Dis,2008,46(12):1813-1821. [6] Roden MM,Zaoutis TE,Buchanan WL,et al.Epidemiology and outcome of zygomycosis:a review of 929 reported cases[J].Clin Infect Dis,2005,41(5):634-653. [7] Rees JR,Pinner RW,Hajjeh RA,et al.The epidemiological features of invasive mycotic infections in the San Francisco Bay area,1992-1993:results of population-based laboratory active surveillance[J].Clin Infect Dis,1998,27(5):1138-1147. [8] Greenberg RN,Scott LJ,Vaughn HH,et al.Zygomycosis (mucormycosis):emerging clinical importance and new treatments[J].Curr Opin Infect Dis,2004,17(6):517-525. [9] 赵静宇,王桂祯,张俊勇,等.中国大陆肺接合菌病102例回顾性分析[J].中国真菌学杂志,2014,9(3):150-154. [10] di CA,Costantino F,Tarani L,et al.Rhinocerebral zygomycosis with pansinusitis in a 14-year-old girl with type 1 diabetes:a case report and review of the literature[J].Ital J Pediatr,2013:doi:10.1186/1824-7288-39-77 [11] Dannaoui E,Meletiadis J,Mouton JW,Meis JF,Verweij PE.In vitro susceptibilities of zygomycetes to conventional and new antifungals[J].J Antimicrob Chemother,2003,51(1):45-52. [12] Singh J,Rimek D,Kappe R.In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method[J].Mycoses,2005,48(4):246-250. [13] Page RL 2nd,Schwiesow J,Hilts A.Posaconazole as salvage therapy in a patient with disseminated zygomycosis:case report and review of the literature[J].Pharmacotherapy,2007,27(2):290-298. [14] van Burik JA,Hare RS,Solomon HF,Corrado ML,Kontoyiannis DP.Posaconazole is effective as salvage therapy in zygomycosis:a retrospective summary of 91 cases[J].Clin Infect Dis,2006,42(7):e61-65. [15] Severo LC,Oliveira FD,Dreher R,Teixeira PZ,Porto ND,Londero AT.Zygomycosis:A report of eleven cases and a review of the Brazilian literature[J].Rev Iberoam Micol,2002,19(1):52-56. |